Medtronic receives FDA clearance for LigaSure RAS

• Medtronic received FDA clearance for the LigaSure RAS Maryland jaw instrument on its Hugo robotic surgery system.
• The device adds vessel-sealing technology to Medtronic’s U.S. robotic-assisted surgery portfolio.
• The instrument was previously introduced in Europe after receiving CE Mark approval in 2025.

Medtronic (NYSE:MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument, expanding the available tools for its Hugo robotic-assisted surgery system in the United States.

The clearance allows U.S. surgeons using the Hugo RAS system to access Medtronic’s LigaSure vessel-sealing technology for robotic-assisted procedures.

The LigaSure RAS Maryland device works with the Valleylab FT10 energy platform to seal and cut vessels, thick tissue, and lymphatics up to 7 mm in diameter in approximately two seconds while aiming to limit thermal spread.

Medtronic said the device is the first robotic-driven LigaSure instrument and is based on technology used in more than 45 million procedures across more than 65 countries.

Medtronic develops medical technologies across surgical, cardiovascular, neuroscience, and other healthcare areas, including robotic-assisted surgery platforms.

The LigaSure RAS Maryland jaw instrument was introduced on the Hugo RAS system in Europe in 2025 following CE Mark approval.